No Data
No Data
Beijing Bohui Innovation Biotechnology Group (300318.SZ): Currently, the company operates 16 pulp stations.
On July 15th, 2024, Beijing Bohui Innovation Biotechnology Group (300318.SZ) accepted a specific object investigation regarding the "planning of the company's pulp station quantity and collection volume". The company replied that it currently operates 16 pulp stations, with Hebei Bohui holding 9 of them, including 3 in Yunnan and 6 in Hebei. Guangdong Weilun holds 7 pulp stations, all of which are located in Guangdong. There are also 7 pulp stations in the stage of waiting for practice licenses or acceptance, with Hebei Bohui holding 5 of them, all of which are located in Yunnan. Three of them have completed the acceptance process and are waiting for practice licenses, and 2 have been completed. Guangdong Weilun holds 2 pulp stations, both of which are located in the interior.
Beijing Bohui Innovation Biotechnology Group (300318.SZ): The production registration application for human coagulation factor VIII is being prepared.
On June 25th, Gelunhui reported that Beijing Bohui Innovation Biotechnology Group (300318.SZ) accepted a specific object's investigation regarding the research and development progress of new products of Hebei Bohui and Guangdong Weilun (recumbent, 8 indicators, chromatographic propofol, etc.). The company replied that human fibronectin is conducting stability research and preclinical research. Human coagulation factor VIII is preparing for production and registration declaration work. The new process of Propofol is undergoing scale-up experimental research.
Beijing Bohui Innovation Biotechnology Group (stock code: 300318.SZ) currently has seven pulp stations in the waiting for practicing licenses or waiting for acceptance stage.
On June 25, 2024, Beijing Bohui Innovation Biotechnology Group (300318.SZ) received a specific research inquiry about "acceptance rhythm and climbing expectations after the construction of the pulp mill." The company responded that there are currently seven pulp mills awaiting professional licenses or acceptance, and three of them, Yunnan Daguang, Yunnan Yongshan, and Yunnan Yiliang, have completed acceptance and are waiting for professional licenses. Inner Mongolia Hulunbuir, Inner Mongolia Tumote Left Banner, Yunnan Yao'an, and Yunnan Luquan are in the preparation stage before acceptance, and the company is actively promoting approval work. The new pulp mill usually has a climbing period of about three years.
Bohui Innovation (300318.SZ): Currently, the in vitro diagnosis business is mainly HPV testing products and trace element testing products
Gelonghui, May 15, 丨 Bohui Innovation (300318.SZ) was surveyed by specific subjects on May 14, 2024, on “Other than HPV and human trace elements, what is the sales status of other IVD products and spectrometers?” The company replied that the company's in vitro diagnostic business is currently mainly HPV testing products and trace element testing products.
Bohui Innovation (300318.SZ): Currently, sales of blood products account for a relatively high proportion of retail sales
Gelonghui, May 15, 丨 Bohui Innovation (300318.SZ) was surveyed by a specific target on May 14, 2024, on “What is the ratio of the company's blood products sales side, hospital side, and retail side? What is the ratio of dealers' sales to their own sales? What is the sales channel situation?” The company replied that the company's current sales of blood products account for a relatively high proportion of sales on the retail side, and the hospital side also has a certain percentage, and the sales method is mainly distribution. At present, the company's sales channels have covered major provinces across the country.
Bohui Innovation (300318.SZ): Currently, the yield rate of albumin and static acrylic remains at the average level of the industry
Gelonghui, May 15, 丨 Bohui Innovation (300318.SZ) was surveyed by specific subjects on May 14, 2024, on “The company's yield rate of albumin and hydroxypropyl?” The company replied that at present, the yield rate of albumin and hydroxypropyl remains at the average level of the industry.
No Data